In 2023, the import of insulin in dosage forms to France was evaluated at a certain baseline value, before a forecasted increase to 979.78 million USD in 2024. Projections indicate a consistent upward trend, with values reaching 1130.8 million USD by 2028. The year-on-year variation reflects a stable growth, with each year showing an approximate increase of around 4% to 5%. Over the five-year forecast period, the compound annual growth rate (CAGR) is expected to average around 3.6%.
Future trends to watch include advancements in insulin production technologies and changes in global health policies. Additionally, increasing diabetes prevalence and innovative delivery methods such as smart insulin pens could drive demand further, affecting import patterns and the broader market dynamics. Monitoring these factors will be crucial for stakeholders in the healthcare and pharmaceutical industries.
